Fierce Pharma

SEPTEMBER 22, 2023

Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.

Clinical Trials 126

Clinical Trials Clinical Trials Trials 126

XTalks

JANUARY 28, 2022

Uveal melanoma is a rare and aggressive type of melanoma of the eye. As such, unresectable or metastatic uveal melanoma usually has a poor prognosis and until the approval of Kimmtrak, there was no approved treatment. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

XTalks

FEBRUARY 27, 2024

Iovance Biotherapeutics’ Amtagvi (lifileucel) won US Food and Drug Administration (FDA) approval last week for the treatment of advanced melanoma, making it the first individualized tumor-infiltrating lymphocyte (TIL) therapy and the first T-cell therapy for a solid tumor to win US regulatory approval.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

pharmaphorum

APRIL 5, 2022

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised.

Sales 52

Sales Protein Drugs Trials 52

XTalks

AUGUST 19, 2022

Along with beti-cel, there is one being developed for sickle cell (approved in Europe as Skysona or eli-cel) and another being jointly developed with Bristol Myers Squibb for melanoma. Zynteglo’s hefty price tag of $2.8 The cells are prepared outside of the body ( ex vivo ) and then infused into the patient.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

Delveinsight

FEBRUARY 25, 2021

DNA hypomethylating agents are epigenetic drugs that eliminate specific chemical tags on DNA, hence turning specific genes on and off and changing the cells’ function. They decided to evaluate the phenomenon further using samples from healthy people and patients with melanoma and breast, ovarian, or colon cancer.

DNA 52

DNA In-Vivo Genetics Medicine 52

XTalks

AUGUST 17, 2020

IL-2 is not only a validated T cell target, but is also an approved drug for metastatic melanoma and renal cell carcinoma. The co-stimulatory IL-2 signal is the same for all of the 100 series molecules (i.e. 101, 102, 103).

Protein 98

Protein Engineer Immune Response In-Vivo 98